Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington's disease

Movement Disorders

Volumn 26, Issue 1, 2011, Pages 130-137

  Ciammola, Andrea ^a   Sassone, Jenny ^a   Sciacco, Monica ^b   Mencacci, Niccolò E ^a   Ripolone, Michela ^b   Bizzi, Caterina ^a   Colciago, Clarissa ^a   Moggio, Maurizio ^b   Parati, Gianfranco ^a,c   Silani, Vincenzo ^a   Malfatto, Gabriella ^a  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Anaerobic threshold; Huntington's disease; Mitochondria; Skeletal muscle

Indexed keywords

LACTIC ACID;

ADULT; AGED; ANAEROBIC THRESHOLD; ARTICLE; BIOSYNTHESIS; CAG REPEAT; CARDIOPULMONARY EXERCISE TEST; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON MICROSCOPY; FEMALE; FUNCTIONAL STATUS; GENE MUTATION; HEART CELL CULTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; HUNTINGTON CHOREA; LACTATE BLOOD LEVEL; LUNG VENTILATION; MALE; MITOCHONDRION; MUSCLE EXERCISE; MYOBLAST; ONSET AGE; OXIDATION KINETICS; PRIORITY JOURNAL; SKELETAL MUSCLE;

ADULT; AGED; ANAEROBIC THRESHOLD; ANALYSIS OF VARIANCE; CELLS, CULTURED; FEMALE; HEART; HUMANS; HUNTINGTON DISEASE; LACTIC ACID; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MIDDLE AGED; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL; RESPIRATION; YOUNG ADULT;

EID: 79951492653     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23258     Document Type: Article

References (36)

1. HDCRG. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983.
2. Sharp AH, Love SJ, Schilling G, et al. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 1995; 14: 1065-1074.
3. Kosinski CM, Schlangen C, Gellerich FN, et al. Myopathy as a first symptom of Huntington's disease in a Marathon runner. Mov Disord 2007; 22: 1637-1640.
4. Busse ME, Hughes G, Wiles CM, Rosser AE. Use of hand-held dynamometry in the evaluation of lower limb muscle strength in people with Huntington's disease. J Neurol 2008; 255: 1534-1540.
5. Hamilton JM, Wosfon T, Peavy GM, Jacobson MW, Corey-Bloom J. Rate and correlates of weight change in Huntington's disease. J Neurol Neurosurg Psychiatr 2004; 75: 209-212.
6. Turner C, Cooper JM, Schapira AH. Clinical correlates of mitochondrial function in Huntington's disease muscle. Mov Disord 2007; 22: 1715-1721.
7. Sathasivam K, Hobbs C, Turmaine M, et al. Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet 1999; 8: 813-822.
8. Ribchester RR, Thoson D, Wood NI, et al. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur J Neurosci 2004; 20: 3092-3114.
9. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 1997; 41: 160-165.
10. Lodi R, Schapira AM, Manners D, et al. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol 2000; 48: 72-76.
11. Saft C, Zange J, Andrich J, et al. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord 2005; 20: 674-679.
12. Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A. Huntington's disease. The current state of research with peripheral tissues. Exp Neurol 2009; 219: 385-397.
13. Nicoli F, Vion-Dury J, Maloteaux JM, et al. CSF and serum metabolic profile of patients with Huntington's chorea: a study by high resolution proton NMR spectroscopy and HPLC. Neurosci Lett 1993; 154: 47-51.
14. Gårseth M, Sonnewald U, White LR, et al. Proton magnetic resonance spectroscopy of cerebrospinal fluid in neurodegenerative disease: indication of glial energy impairment in Huntington chorea, but not Parkinson disease. J Neurosci Res 2000; 60: 779-782.
15. Reynolds NC, Jr, Prost RW, Mark LP. Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease. Brain Res 2005; 1031: 82-89.
16. Martin WR, Wieler M, Hanstock CC. Is brain lactate increased in Huntington's disease? J Neurol Sci 2007; 263: 70-74.
17. Morgan-Hughes JA. Mitochondrial diseases of muscle. Curr Opin Neurol 1994; 7: 457-462.
18. Shapira AHV, DiMauro S. Mitochondrial disorders in Neurology. Boston, MA: Butterworth and Heinemann; 1994.
19. Wasserman K. Critical capillary PO2 and the role of lactate production in oxyhemoglobin dissociation during exercise. Adv Exp Med Biol 1999; 471: 321-333.
20. Ciammola A, Sassone J, Alberti L, et al. Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects. Cell Death Differ 2006; 13: 2068-2078.
21. Sciacco M., Fagiolari G., Lamperti C, et al. Lack of apoptosis in mitochondrial encephalomyopathies. Neurology 2001; 56: 1070-1074.
22. Agostoni PG, Guazzi M, Bussotti M, Grazi M, Palermo P, Marenzi G. Lack of improvement of lung diffusing capacity following fluid withdrawal by ultrafiltration in chronic heart failure. J Am Coll Cardiol 2000; 36: 1600-1604.
23. Busse ME, Khalil H, Quinn L, Rosser AE. Physical therapy intervention for people with Huntington disease. Phys Ther 2008; 88: 820-831.
24. Albouaini K, Egred M, Alahmar A, Wright DJ. Cardiopulmonary exercise testing and its application. Heart 2007; 93: 1285-1292.
25. Tanaka H, Shindo M. The benefits of the low intensity training. Ann Physiol Anthropol 1992; 11: 365-368.
26. Goebel HH, Heipertz R, Scholz W, Iqbal K, Tellez-Nagel I. Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies. Neurology 1978; 28: 23-31.
27. Tellez-Nagel I, Johnson AB, Terry RD. Studies on brain biopsies of patients with Huntington's chorea. J Neuropathol Exp Neurol 1974; 33: 308-332.
28. Quintanilla RA, Johnson GV. Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease. Brain Res Bull 2009; 80: 242-247.
29. Squitieri F, Falleni A, Cannella M, et al. Abnormal morphology of peripheral cell tissues from patients with Huntington disease. J Neural Transm 2010; 117: 77-83.
30. Mihm MJ, Amann DM, Schanbacher BL, Altschuld RA, Bauer JA, Hoyt KR. Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2007; 25: 297-308.
31. Lanska DJ, Lanska MJ, Lavine L, Schoenberg BS. Conditions associated with Huntington's disease at death. A case-control study. Arch Neurol 1988; 45: 878-880.
32. Piepoli MF, Corrà U, Agostoni PG, et al. Statement on cardiopulmonary exercise testing in chronic heart failure due to left ventricular dysfunction. recommendations for performance and interpretation. Part I: definition of cardiopulmonary exercise testing parameters for appropriate use in chronic heart failure. Eur J Cardiovasc Prev Rehabil 2006; 13: 150-164.
33. Sassone J, Colciago C, Marchi P, et al. Mutant Huntingtin induces activation of the Bcl-2/adenovirus E1B 19-kDa interacting protein (BNip3). Cell Death Dis 2010, 1, e7; doi:10.1038/cddis.2009.6
34. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1 alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006; 127: 59-69.
35. Chaturvedi RK, Adhihetty P, Shukla S, et al. Impaired PGC-1 {alpha}function in muscle in Huntington's disease. Hum Mol Genet 2009; 18: 3048-3065.
36. Mc Gill JK, Beal MF. PGC-1 alpha, a new therapeutic target in Huntington's disease? Cell 2006; 127: 465-468.